10x Genomics, Inc.

NasdaqGS:TXG Voorraadrapport

Marktkapitalisatie: US$2.4b

De vertaling van deze pagina is experimenteel en in ontwikkeling. Uw is welkom!

10x Genomics Toekomstige groei

Future criteriumcontroles 1/6

10x Genomics zal naar verwachting groeien in winst en omzet met respectievelijk 52.3% en 9.4% per jaar. De winst per aandeel zal naar verwachting groeien met 53.9% per jaar. Het rendement op het eigen vermogen zal over 3 jaar naar verwachting -7.2% zijn.

Belangrijke informatie

52.3%

Groei van de winst

53.9%

Groei van de winst per aandeel

Life Sciences winstgroei17.5%
Inkomstengroei9.4%
Toekomstig rendement op eigen vermogen-7.2%
Dekking van analisten

Good

Laatst bijgewerkt02 Oct 2024

Recente toekomstige groei-updates

Recent updates

10x Genomics Is Still A Long Way From Profitability

Oct 03

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Sep 09
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

Aug 10
Investors Still Aren't Entirely Convinced By 10x Genomics, Inc.'s (NASDAQ:TXG) Revenues Despite 30% Price Jump

10x Genomics Stock Slips As Illumina Snaps Up Competitor - Tough Times Ahead

Jul 10

10x Genomics: Sticking To The Plan To Avoid The Falling The Knife

Jun 21

Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

Jun 14
Take Care Before Jumping Onto 10x Genomics, Inc. (NASDAQ:TXG) Even Though It's 26% Cheaper

10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

May 21
10x Genomics (NASDAQ:TXG) Is In A Strong Position To Grow Its Business

Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Apr 15
Why We're Not Concerned About 10x Genomics, Inc.'s (NASDAQ:TXG) Share Price

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Feb 05
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

10x Genomics: Sales Are Growing At A Rapid Rate, But So Are Expenses

Jan 20

Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

Dec 22
Revenues Tell The Story For 10x Genomics, Inc. (NASDAQ:TXG) As Its Stock Soars 31%

We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Nov 03
We're Hopeful That 10x Genomics (NASDAQ:TXG) Will Use Its Cash Wisely

Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Aug 04
Here's Why We're Not Too Worried About 10x Genomics' (NASDAQ:TXG) Cash Burn Situation

Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

Jun 04
Why Investors Shouldn't Be Surprised By 10x Genomics, Inc.'s (NASDAQ:TXG) P/S

At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

Apr 29
At US$52.43, Is 10x Genomics, Inc. (NASDAQ:TXG) Worth Looking At Closely?

10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

Mar 24
10x Genomics, Inc. (NASDAQ:TXG) Shares Could Be 28% Below Their Intrinsic Value Estimate

We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Feb 02
We're Interested To See How 10x Genomics (NASDAQ:TXG) Uses Its Cash Hoard To Grow

Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

Jan 12
Is Now The Time To Look At Buying 10x Genomics, Inc. (NASDAQ:TXG)?

An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

Dec 22
An Intrinsic Calculation For 10x Genomics, Inc. (NASDAQ:TXG) Suggests It's 39% Undervalued

10x Genomics: No Signs Of A Growth Turnaround, Heavy Bearish Momentum

Oct 12

Winst- en omzetgroeiprognoses

NasdaqGS:TXG - Toekomstschattingen van analisten en financiële gegevens uit het verleden (USD Millions )
DatumInkomstenInkomstenVrije kasstroomGeldmiddelen uit operationele activiteitenGem. Aantal analisten
12/31/2026789-49-329310
12/31/2025717-108-1095916
12/31/2024648-159-169616
6/30/2024632-240-33-8N/A
3/31/2024625-264-74-27N/A
12/31/2023619-255-65-15N/A
9/30/2023591-223-113-27N/A
6/30/2023568-172-118-11N/A
3/31/2023536-174-126-17N/A
12/31/2022516-166-165-34N/A
9/30/2022504-167-161-42N/A
6/30/2022498-142-161-58N/A
3/31/2022499-89-129-38N/A
12/31/2021490-58-123-21N/A
9/30/2021459-455-253-157N/A
6/30/2021406-504-264-187N/A
3/31/2021333-533-289-219N/A
12/31/2020299-543-256-218N/A
9/30/2020262-134-104-81N/A
6/30/2020251-78-46-11N/A
3/31/2020264-49-1923N/A
12/31/2019246-31-835N/A
9/30/2019221-100-62-23N/A
6/30/2019197-105-69-43N/A
3/31/2019170-105-71-57N/A
12/31/2018146-112-83-76N/A
12/31/201771-19N/A-11N/A

Toekomstige groeivoorspellingen analisten

Verdiensten versus spaarpercentage: De verwachting is dat TXG de komende 3 jaar verliesgevend zal blijven.

Winst versus markt: De verwachting is dat TXG de komende 3 jaar verliesgevend zal blijven.

Hoge groeiwinsten: De verwachting is dat TXG de komende 3 jaar verliesgevend zal blijven.

Omzet versus markt: De omzet van TXG ( 9.4% per jaar) zal naar verwachting sneller groeien dan de markt US ( 8.7% per jaar).

Hoge groei-inkomsten: De omzet van TXG ( 9.4% per jaar) zal naar verwachting langzamer groeien dan 20% per jaar.

Groeiprognoses winst per aandeel

Toekomstig rendement op eigen vermogen

Toekomstige ROE: Er wordt voorspeld dat TXG binnen 3 jaar verliesgevend zal zijn.

Ontdek groeibedrijven

7D

1Y

7D

1Y

7D

1Y